ConductScience.org, home

Paper9736552

Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.

Kaul S and 4 others. Antimicrob Agents Chemother, 1998. Cited by 17 papers, by iCite.

Cite this record

ConductScience Library. Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection. Papers, record 9736552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9736552

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1998
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
0.78
iCite
Revised in PubMed
2024-03-15
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kaul SS
2Christofalo BB
3Raymond RHR H
4Stewart MBM B
5Macleod CMC M

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-HIV AgentsMajor topic
HIV InfectionsMajor topic
StavudineMajor topic
Adolescent
Adult
Biological Availability
Cross-Over Studies
Female
Food
Humans
Male

Source PubMed

Download CSV of topics

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18366182Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation.J Clin Pharmacol1993https://conductscience.org/library/papers/8366182PubMed
28239589In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8239589PubMed
37861015Biologic effects and safety of stavudine: overview of phase I and II clinical trials.J Infect Dis1995https://conductscience.org/library/papers/7861015PubMed
42852679Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.J Clin Pharmacol1988https://conductscience.org/library/papers/2852679PubMed
57856987Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.Ann Intern Med1995https://conductscience.org/library/papers/7856987PubMed
61389940The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients.Br J Clin Pharmacol1992https://conductscience.org/library/papers/1389940PubMed
77780046Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: application to bioequivalence assessment of various capsule formulations.Biopharm Drug Dispos1995https://conductscience.org/library/papers/7780046PubMed
82111751Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.Clin Pharmacol Ther1990https://conductscience.org/library/papers/2111751PubMed
97630678A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.Pediatrics1995https://conductscience.org/library/papers/7630678PubMed
1080933632',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial.J Infect Dis1993https://conductscience.org/library/papers/8093363PubMed
112060570Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal.Eur J Clin Pharmacol1991https://conductscience.org/library/papers/2060570PubMed
127963708Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.J Infect Dis1994https://conductscience.org/library/papers/7963708PubMed
138709213
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
J Virol1996https://conductscience.org/library/papers/8709213PubMed
148933418Specific radioimmunoassays for the measurement of stavudine in human plasma and urine.J Pharm Biomed Anal1996https://conductscience.org/library/papers/8933418PubMed
159758571Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection.Ann Intern Med1998https://conductscience.org/library/papers/9758571PubMed
163165603Pharmacokinetics and bioavailability of zidovudine in humans.Am J Med1988https://conductscience.org/library/papers/3165603PubMed
178390811Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8390811PubMed
181323615Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex.J Infect Dis1992https://conductscience.org/library/papers/1323615PubMed
192350441Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal.AIDS1990https://conductscience.org/library/papers/2350441PubMed
207861017Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.J Infect Dis1995https://conductscience.org/library/papers/7861017PubMed

See all 29 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
36318429Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses.AIDS Behav2023https://conductscience.org/library/papers/36318429PubMed
25697412Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.Int J Antimicrob Agents2015https://conductscience.org/library/papers/25697412PubMed
19942751Pharmacokinetics of lamivudine & stavudine in generic fixed-dose combinations in HIV-1 infected adults in India.Indian J Med Res2009https://conductscience.org/library/papers/19942751PubMed
10595868Stavudine: an update of its use in the treatment of HIV infection.Drugs1999https://conductscience.org/library/papers/10595868PubMed
10511919Effects of food on clinical pharmacokinetics.Clin Pharmacokinet1999https://conductscience.org/library/papers/10511919PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9736552

GET https://conductscience.org/api/papers/v1/9736552/references?page=2